Could electromagnetic fields help fight breast cancer?

NCT ID NCT07227831

Not yet recruiting Disease control Sponsor: Barbara Ann Karmanos Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a device called TheraBionic P1 that sends low-level electromagnetic fields to the body. It is for people with advanced hormone-positive, HER2-negative breast cancer who have already tried standard treatments. The goal is to see if the device can help control the cancer and improve survival, while also checking its safety and tolerability.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TheraBionic P1 device (amplitude-modulated electromagnetic fields)
What this could lead to: If it works, this could offer a new, non-invasive option to help control advanced breast cancer and extend survival when other treatments have stopped working.
What could go wrong: This is an early phase 2 trial with only 82 participants, so results may not apply to everyone. The device is experimental and it is unknown if it will meaningfully improve survival or quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm Her2-receptor negative breast cancer hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED BREAST CANCER HER2-NEGATIVE BREAST CANCER HORMONE RECEPTOR POSITIVE TUMOR METASTATIC BREAST CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.